respiratori
virus
may
caus
seriou
morbid
mortal
immunocompromis
host
transplant
recipi
appear
particularli
vulner
impact
infect
respiratori
virus
subsequ
develop
sever
lower
respiratori
tract
diseas
increasingli
appreci
respiratori
virus
becom
readili
detect
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
among
bestdocu
respiratori
virus
caus
wide
rang
respiratori
diseas
transplant
recipi
rang
asymptomat
shed
fatal
respiratori
failur
understand
epidemiolog
clinic
characterist
rsv
hmpv
permit
clinician
interven
pretranspl
provid
appropri
infect
control
prevent
measur
potenti
treat
patient
manag
immunosuppress
therapi
sever
respiratori
diseas
serious
immunocompromis
host
midtwentieth
centuri
origin
attribut
infect
opportunist
pathogen
gramneg
bacteria
fungi
pneumocysti
jiroveci
mycobacteria
well
cytomegaloviru
cmv
adenoviru
later
twentieth
centuri
episod
acut
upper
respiratori
infect
uri
lrti
without
identifi
etiolog
often
consid
idiopath
pneumonia
attribut
regimenrel
toxic
acut
respiratori
distress
syndrom
ard
classic
studi
nonbacteri
nonfung
pneumonia
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
episod
pneumonia
remain
undiagnos
overal
mortal
rate
associ
idiopath
pneumonia
hsct
recipi
strikingli
high
figur
potenti
morbid
rsv
infect
first
recogn
immunocompromis
children
decad
earlier
immunocompromis
adult
recognit
respiratori
virus
import
clinic
problem
like
reflect
increas
number
sever
immunodefici
patient
aggress
attempt
identifi
caus
respiratori
ill
highrisk
patient
increas
abil
clinic
virolog
patholog
laboratori
identifi
respiratori
virus
clinic
specimen
although
uncommon
atyp
pathogen
may
respons
respiratori
diseas
transplant
recipi
virus
caus
typic
mild
acut
respiratori
ill
gener
popul
respons
hospit
person
age
underli
medic
condit
virus
also
common
caus
respiratori
diseas
transplant
recipi
widespread
avail
sensit
reliabl
molecular
diagnost
method
rsv
hmpv
detect
worldwid
transplant
recipi
shown
common
caus
respiratori
diseas
immunocompromis
host
gener
popul
well
transplant
recipi
rsv
hmpv
may
produc
wide
constel
clinic
syndrom
rang
common
cold
bronchiol
sever
pneumonia
contrast
gener
popul
rsv
hmpv
may
significantli
impact
morbid
mortal
transplant
recipi
rsv
first
identifi
becam
appreci
major
caus
epidem
bronchiol
pneumonia
young
children
hmpv
first
identifi
molecular
techniqu
symptomat
children
van
den
hoogen
et
al
paramyxoviru
caus
bronchiol
uri
children
virus
classifi
within
pneumovirina
subfamili
paramyxovirida
famili
nonseg
negativestrand
envelop
rna
virus
hmpv
belong
metapneumoviru
genu
wherea
rsv
member
pneumoviru
genu
virus
highli
pleomorph
size
vari
nm
rsv
hmpv
genom
approxim
kb
length
close
resembl
exclud
differ
order
gene
absenc
nonstructur
gene
hmpv
genom
remain
eight
gene
code
nine
protein
present
virus
nucleoprotein
n
protein
phosphoprotein
p
protein
matrix
protein
protein
fusion
glycoprotein
f
protein
put
transcript
factor
protein
rna
synthesi
regulatori
factor
protein
small
hydrophob
glycoprotein
sh
protein
attach
glycoprotein
g
protein
viral
polymeras
l
protein
rna
core
virion
associ
p
n
l
protein
surround
protein
cover
lipid
envelop
f
highli
conserv
envelop
glycoprotein
within
viru
rsv
hmpv
fusion
glycoprotein
essenti
promot
attach
fusion
viru
cell
membran
viral
entri
fusion
protein
target
mani
vaccin
develop
well
monoclon
antibodi
palivizumab
use
prevent
rsv
diseas
preterm
infant
contrast
g
gene
variabl
whole
genom
analysi
rsv
hmpv
shown
exist
two
genotyp
b
hmpv
two
major
genet
group
divid
subgroup
base
upon
sequenc
variabl
g
f
gene
subgroup
divid
rsv
hmpv
infect
produc
humor
cellular
immun
respons
humor
immun
protect
reinfect
cellular
immun
control
establish
infect
termin
viral
shed
protect
immun
immunocompet
host
thought
rel
shortliv
virus
interfer
host
innat
immun
system
result
incomplet
clearanc
partial
immun
character
rsv
hmpv
strainsobtain
cultur
directli
clinic
specimen
frequent
desir
antigen
differ
among
viru
strain
isol
differ
geograph
locat
differ
time
may
also
examin
pool
monoclon
antibodi
rna
fingerprint
use
analysi
rsv
strain
nosocomi
outbreak
direct
sequenc
f
g
glycoprotein
commonli
util
nextgener
sequenc
promis
tool
character
rsv
hmpv
strain
sever
infect
could
provid
inform
phylogen
identifi
outbreak
also
detect
mutat
could
associ
antivir
monoclon
resist
well
increas
virul
human
gene
allel
human
genom
may
increas
rsv
sever
infant
littl
known
yet
genom
variat
transplant
recipi
nextgener
sequenc
potenti
provid
inform
viru
human
genom
simultan
rsv
well
known
caus
annual
winter
outbreak
commun
figur
surveil
studi
respiratori
virus
transplant
center
establish
high
frequenc
signific
clinic
impact
respiratori
viral
infect
hsct
recipi
overal
well
rel
import
rsv
term
morbid
mortal
tabl
retrospect
review
conduct
children
hospit
philadelphia
reveal
respiratori
viral
infect
pediatr
hsct
patient
one
infect
due
rsv
one
earliest
studi
demonstr
fatal
rsv
pneumonia
four
immunocompromis
adult
hsct
solid
organ
transplant
recipi
rsv
infect
studi
conduct
twentieth
centuri
util
classic
virolog
method
rel
insensit
detect
rsv
andor
detect
recent
describ
respiratori
virus
hmpv
thu
studi
like
underestim
true
frequenc
rsv
overal
nonetheless
earli
studi
larg
transplant
center
report
seriou
sequela
small
number
patient
develop
pneumonia
rsv
detect
fred
hutchinson
cancer
research
center
hutch
prospect
surveil
studi
conduct
document
respiratori
viral
infect
immunocompromis
patient
follow
hospit
discharg
five
patient
develop
pneumonia
two
patient
die
one
rsv
adenoviru
subsequ
prospect
surveil
studi
describ
viral
infect
reveal
overal
frequenc
viral
infect
approxim
rsv
isol
bal
studi
demonstr
rel
high
number
patient
rsv
lower
respiratori
tract
diseas
higher
rate
lrti
caus
piv
influenza
rhinoviru
result
viral
surveil
transplant
unit
vari
depend
type
surveil
protocol
util
time
year
surveil
conduct
type
clinic
sampl
evalu
laboratori
test
util
hudding
univers
hospit
stockholm
prospect
surveil
studi
conduct
among
hsct
recipi
detect
respiratori
viral
infect
patient
includ
rsv
md
anderson
cancer
center
mdacc
prospect
surveil
conduct
use
cultur
techniqu
among
hospit
adult
hsct
recipi
two
winter
period
detect
respiratori
viral
infect
hospit
patient
acut
respiratori
symptom
nearli
half
due
rsv
patient
impact
ill
consider
patient
rsv
infect
progress
pneumonia
patient
rsv
pneumonia
die
winter
period
commun
virus
frequent
nosocomi
transmiss
high
frequenc
mortal
respiratori
viralassoci
pneumonia
four
time
high
cmvassoci
pneumonia
recent
prospect
studi
conduct
transplant
center
worldwid
continu
demonstr
import
rsv
report
incid
infect
risk
factor
fatal
diseas
tabl
studi
barcelona
spain
describ
incid
symptomat
respiratori
viral
infect
patient
follow
sever
year
posttranspl
altogeth
allogen
hsct
recipi
autolog
hsct
recipi
respiratori
virus
detect
patient
receiv
either
autolog
allogen
transplant
symptomat
rsv
diseas
risk
factor
associ
respiratori
viru
identifi
includ
close
household
contact
children
age
year
chronic
graft
versu
host
diseas
lymphopenia
identifi
major
risk
uri
progress
similar
rate
demonstr
center
usa
south
america
europ
less
data
avail
document
impact
rsv
sot
recipi
tabl
rsv
shown
caus
lower
respiratori
tract
diseas
associ
complic
organ
reject
bronchiol
obliteran
lung
transplant
recipi
highest
rate
rsv
lower
respiratori
tract
diseas
divers
type
organ
transplant
rsv
infect
lung
transplant
recipi
also
associ
organ
reject
progress
bronchiol
obliteran
observ
season
relat
adult
renal
transplant
recipi
also
report
develop
rsvassoci
lower
respiratori
tract
diseas
mortal
low
patient
recov
without
specif
antivir
therapi
rsv
infect
pediatr
liver
transplant
recipi
associ
signific
morbid
rel
low
mortal
among
pediatr
liver
transplant
recipi
care
univers
pittsburgh
children
develop
rsv
infect
threequart
nosocomi
acquir
major
children
lower
respiratori
tract
involv
two
children
die
specif
antivir
therapi
administ
risk
factor
sever
diseas
includ
onset
infect
earli
transplant
preexist
lung
patholog
augment
immunosuppress
prompt
reject
younger
age
infect
occur
late
transplant
absenc
reject
usual
sever
intens
prospect
approach
determin
incid
risk
factor
respiratori
virus
carri
hutch
among
hsct
recipi
prospect
enrol
test
weekli
day
posttranspl
use
cultur
rtpcr
detect
method
cumul
incid
estim
hmpv
rsv
day
similar
respect
multivari
analysi
demonstr
recipi
cmv
seroposit
associ
increas
risk
acquisit
respiratori
viru
hazard
ratio
ci
p
frequenc
rsv
infect
associ
morbid
mortal
differ
substanti
potenti
account
variabl
report
differ
institut
differ
reflect
intens
viral
surveil
time
surveil
virus
preval
commun
degre
immunosuppress
patient
infect
control
polici
inclus
potenti
well
actual
transplant
recipi
surveil
outpati
well
inpati
type
laboratori
assay
util
case
definit
util
ie
clinic
laboratori
definit
hmpv
detectedworldwid
season
distribut
commun
outbreak
occur
yearli
mainli
winter
spring
januari
may
northern
hemispher
june
juli
southern
hemispher
figur
often
hmpv
outbreak
concomit
subsequ
rsv
outbreak
hmpv
commonli
affect
young
children
less
year
old
second
rsv
caus
bronchiol
seropreval
studi
shown
high
percentag
children
contract
viru
age
year
howev
reinfect
occur
later
secondari
insuffici
immun
infect
differ
genotyp
predomin
hmpv
strain
vari
locat
locat
year
year
vicent
et
al
report
higher
virul
genotyp
papenburg
et
al
report
higher
virul
genotyp
b
howev
interact
impact
hmpv
virus
bacteria
remain
unclear
particularli
immunocompromis
patient
import
hmpv
transplant
recipi
well
studi
rsv
tabl
first
report
shortli
detect
hmpv
boivin
et
al
earli
prospect
longitudin
studi
spain
document
hmpv
autolog
allogen
hsct
recipi
incid
clinic
impact
hmpv
rsv
diseas
document
quit
similar
one
earli
prospect
studi
document
hmpv
infect
adult
hematolog
malign
progress
upper
respiratori
infect
pneumonia
case
fatal
rate
close
lower
respiratori
tract
diseas
pneumonia
due
hmpv
infect
hsct
recipi
report
overal
incid
singl
case
seri
describ
hmpvposit
nasal
aspir
sampl
adult
follow
hsct
mani
asymptomat
studi
demonstr
high
rate
genet
similar
virus
differ
studi
due
high
rate
genet
ident
virus
author
suggest
hmpv
infect
may
origin
hospit
nosocomi
nonetheless
studi
outlier
compar
report
hmpv
transplant
center
pneumonia
rate
follow
hmpv
infect
report
mortal
rate
among
hsct
recipi
underw
bal
investig
lower
respiratori
tract
diseas
pulmonari
infiltr
radiograph
imag
hmpv
detect
bal
sampl
patient
four
five
die
acut
respiratori
failur
highlight
potenti
sever
hmpv
pneumonia
retrospect
cohort
studi
hutch
describ
high
mortal
rate
among
patient
hmpv
pneumonia
rate
similar
rsv
pneumonia
mortal
studi
transplant
unit
continu
document
potenti
hmpv
caus
sever
lower
respiratori
tract
diseas
clinic
present
outcom
gener
similar
rsv
signific
hmpv
infect
sot
recipi
remain
less
well
defin
except
hmpv
diseas
lung
transplant
recipi
case
report
sever
diseas
describ
follow
liver
renal
transplant
rate
hmpv
infect
lung
transplant
recipi
report
similar
seen
studi
hsct
recipi
vari
patient
hmpv
appear
frequent
sole
pathogen
detect
detect
hmpv
lung
transplant
recipi
may
necessarili
signifi
diseas
note
studi
lung
transplant
recipi
undergo
bal
mainli
surveil
purpos
four
case
hmpv
detect
asymptomat
patient
hmpv
infect
found
lung
transplant
recipi
preval
may
higher
nosocomi
outbreak
one
studi
set
commun
outbreak
identifi
hmpv
bal
sampl
patient
clinic
present
vari
asymptomat
infect
sever
diseas
acut
allograft
reject
frequent
hmpvinfect
group
nonhmpvinfect
group
vs
respect
p
overal
mortal
also
higher
vs
respect
p
anoth
prospect
studi
found
hmpv
infect
frequent
rsv
lung
transplant
caus
much
pneumonia
acut
allograft
dysfunct
vs
respect
rsv
associ
chronic
allograft
dysfunct
month
anoth
studi
hmpv
infect
lung
transplant
recipi
associ
acut
allograft
dysfunct
compar
rsv
metaanalysi
hmpv
respiratori
infect
allograft
reject
among
lung
transplant
recipi
indic
detect
hmpv
airway
secret
may
signific
posttransplant
occurr
total
sampl
lung
transplant
recipi
analyz
viru
detect
sampl
virus
identifi
posit
hmpv
twenti
case
hmpv
acut
reject
within
month
viral
detect
five
case
chronic
reject
associ
hmpv
studi
includ
metaanalysi
except
one
identifi
reject
within
month
anoth
studi
also
describ
case
chronic
reject
within
month
diseas
manifest
rsv
depend
mani
factor
includ
immun
immun
compet
host
time
infect
relat
transplant
type
transplant
age
underli
health
patient
degre
durat
immunodefici
rsv
infect
hsct
recipi
typic
follow
clinic
sequenc
rsv
infect
previous
healthi
children
sign
symptom
uri
rhinorrhea
sinu
congest
sore
throat
otiti
media
frequent
preced
sign
lower
respiratori
tract
diseas
includ
cough
wheez
hypoxia
pneumonia
tabl
presenc
wheez
respiratori
symptom
respiratori
viru
season
may
provid
clue
rsv
may
present
progress
uri
lri
associ
patient
earli
month
posttranspl
lymphopenia
sever
immunosuppress
hsct
patient
recent
engraft
frequenc
progress
lri
tract
diseas
rang
tabl
pneumonia
follow
rsv
infect
may
primarili
viral
bacteri
fungal
mix
origin
rsv
diseas
progress
respiratori
failur
howev
mortal
remain
high
despit
use
antivir
therapi
immunotherapi
decreas
immunosuppress
therapi
fatal
rate
rsv
pneumonia
rang
recent
case
seri
earlier
studi
risk
factor
progress
rsv
upper
respiratori
diseas
lower
tract
diseas
pneumonia
factor
relat
fatal
diseas
evalu
common
risk
factor
describ
multipl
center
use
differ
method
case
ascertain
viral
detect
remain
lymphopenia
prospect
multicent
studi
carri
european
group
blood
marrow
transplant
lymphopenia
neutropenia
significantli
increas
risk
lower
respiratori
tract
diseas
older
age
donor
statu
also
signific
risk
factor
studi
wherea
cmv
serostatu
acut
graft
versu
host
diseas
time
rel
engraft
preemptiv
aerosol
ribavirin
low
dose
h
daili
signific
investig
mdacc
demonstr
season
year
relaps
malign
presenc
graft
versu
host
diseas
increas
age
lack
engraft
inpati
risk
factor
develop
rsv
pneumonia
recent
larg
retrospect
studi
identifi
graft
sourc
includ
cord
marrow
adjust
hazard
ratio
hr
ci
oxygen
requir
adjust
hr
ci
independ
associ
death
due
respiratori
failur
hsct
recipi
smoke
histori
condit
highdos
total
bodi
irradi
absolut
lymphocyt
count
time
uri
onset
also
significantli
associ
diseas
progress
sinc
initi
therapi
hing
prompt
diagnosi
possibl
fals
neg
laboratori
test
must
consid
individu
patient
diagnosi
aggress
pursu
mean
bal
regardless
therapeut
intervent
high
rate
mortal
due
rsv
pneumonia
document
serious
immunocompromis
patient
therapi
initi
develop
respiratori
failur
figur
surviv
rate
remain
low
sever
immunosuppress
patient
intub
due
progress
rsv
pneumonia
unrel
superimpos
pulmonari
hemorrhag
pulmonari
edema
bacteri
superinfect
hmpv
may
caus
upper
lowerrespiratori
tract
infect
hsct
recipi
asymptomat
shed
upper
respiratori
tract
report
indic
hmpv
infect
result
sever
lower
tract
diseas
hsct
recipi
hmpv
diseas
immedi
posttranspl
period
typic
present
respiratori
symptom
includ
nasal
congest
sore
throat
cough
fever
lower
respiratori
tract
diseas
develop
rapidli
progress
pulmonari
infiltr
frequent
accompani
hypotens
septic
shock
may
present
figur
c
prospect
viral
surveil
hsct
recipi
sampl
respiratori
virus
obtain
weekli
regardless
presenc
respiratori
symptom
cumul
incid
estim
hmpv
ci
year
determin
case
hmpv
clinic
respiratori
symptom
identifi
rang
mild
sever
diseas
singl
multipl
symptom
tabl
among
hsct
recipi
hmpv
detect
rtpcr
bal
posit
hmpv
rtpcr
nasal
wash
sampl
within
day
prior
follow
bal
viral
rna
detect
serum
one
sever
immunocompromis
hsct
recipi
two
time
point
day
apart
viral
load
copiesml
sampl
patient
die
sever
respiratori
diseas
assess
risk
factor
associ
overal
mortal
day
posttranspl
use
bone
marrow
stem
cell
sourc
steroid
treatment
oxygen
use
associ
overal
mortal
radiograph
find
associ
hmpv
infect
hsct
recipi
may
consist
centrilobular
nodul
ground
glass
opac
treeinbud
diffus
bilater
alveolar
infiltr
figur
centrilobular
nodul
associ
less
mechan
ventil
ground
glass
opac
tend
associ
increas
rate
hypoxemia
alveolar
consolid
correspond
extens
damag
histolog
examin
histolog
evalu
also
shown
hyalin
membran
format
foci
bronchiol
obliteran
organ
pneumonia
diffus
alveolar
hemorrhag
variabl
diseas
sever
report
follow
hmpv
infect
sot
recipi
one
studi
lung
transplant
recipi
hmpv
detect
four
symptomat
one
asymptomat
patient
viral
infect
persist
resolv
without
major
complic
anoth
studi
nine
lung
transplant
recipi
hmpv
compar
transplant
recipi
without
hmpv
infect
hmpv
infect
associ
sign
acut
graft
reject
increas
overal
mortal
three
nine
hmpvinfect
patient
die
none
die
hmpvneg
group
outbreak
respiratori
virus
occur
annual
commun
potenti
patient
famili
health
care
worker
becom
infect
follow
exposur
outsid
hospit
howev
nosocomi
transmiss
within
hospit
set
becom
seriou
concern
high
rate
morbid
mortal
immunocompromis
patient
document
nosocomi
outbreak
hospitalbas
oubreak
rsv
infect
hsct
recipi
occur
introduct
circul
commun
strain
well
transmiss
ident
viral
strain
among
patient
outbreak
rsv
associ
high
mortal
rate
rang
infect
patient
transmiss
ident
strain
rsv
within
outpati
set
hospit
set
also
shown
demonstr
import
infect
control
measur
inpati
outpati
set
nosocomi
transmiss
hmpv
also
occur
outbreak
possibl
inpati
outpati
unit
one
studi
patient
diagnos
hmpv
within
week
tertiari
care
cancer
unit
molecular
subtyp
reveal
infect
genotyp
viru
implic
nosocomi
transmiss
four
patient
die
hmpvassoci
pneumonia
consequ
multiorgan
failur
current
option
antivir
therapi
rsv
diseas
immunocompromis
host
limit
larg
control
therapeut
trial
rsv
pneumonia
lower
tract
diseas
immunocompromis
patient
conduct
aerosol
ribavirin
licens
usa
therapi
rsv
bronchiol
pneumonia
infant
young
children
antivir
agent
current
util
treatment
rsv
diseas
immunocompromis
patient
gener
ribavirin
given
inhal
aerosol
solut
via
face
mask
protect
environ
scaveng
tent
protect
health
care
worker
potenti
drug
contamin
ribavirin
initi
licens
use
given
hday
use
intermitt
aerosol
ribavirin
given
h
three
time
daili
found
similar
effect
hday
continu
infus
ribavirin
healthi
children
util
adult
eas
administr
enhanc
toler
random
trial
hsct
patient
risk
lrti
evalu
intermitt
dose
ribavirin
given
h
three
time
daili
versu
continu
ribavirin
administr
use
adapt
random
trial
design
hsct
patient
author
conclud
intermitt
schedul
prefer
eas
administr
evid
higher
efficaci
one
random
control
multicent
clinic
trial
aerosol
ribavirin
prevent
rsv
diseas
progress
lri
conduct
hsct
recipi
earli
posttranspl
despit
enrol
period
sever
year
patient
enrol
none
ten
patient
random
high
dose
short
durat
aerosol
ribavirin
administ
ml
water
given
h
three
time
daili
diseas
progress
compar
control
patient
trend
statist
signific
p
viral
load
appear
reduc
ribavirin
treatment
rebound
cessat
therapi
data
demonstr
effect
ribavirin
mainli
retrospect
open
trial
adult
hsct
recipi
rsvinduc
acut
lung
injuri
monotherapi
aerosol
ribavirin
report
benefit
initi
prior
develop
radiograph
infiltr
anoth
open
trial
adult
hsct
recipi
radiograph
proven
rsv
pneumonia
combin
therapi
aerosol
ribavirin
high
rsvtiter
ivig
report
benefit
initi
prior
onset
respiratori
failur
retrospect
mdacc
studi
confirm
rsv
infect
allogen
hsct
recipi
util
multivari
logist
regress
demonstr
lack
ribavirin
aerosol
therapi
upper
respiratori
tract
diseas
stage
import
risk
factor
associ
rsv
lrti
allcaus
mortal
retrospect
studi
hsct
recipi
confirm
lower
respiratori
tract
rsv
infect
base
analysi
bronchoalveolar
lavag
fluid
hutch
viral
rna
detect
blood
detect
patient
median
day
follow
diagnosi
lower
respiratori
tract
diseas
neutropenia
thrombocytopenia
mechan
ventil
increas
risk
rsv
rna
detect
plasma
serum
lymphopenia
steroid
use
detect
rsv
rna
serum
plasma
increas
risk
overal
mortal
adjust
hazard
ratio
ahr
p
data
solid
organ
transplant
recipi
even
limit
favor
respons
report
open
trial
lung
transplant
recipi
lower
respiratori
tract
diseas
receiv
monotherapi
aerosol
ribavirin
well
open
trial
oral
ribavirin
although
control
studi
perform
oral
ribavirin
found
welltoler
result
less
hospit
less
expens
intraven
inhal
ribavirin
retrospect
studi
lung
transplant
recipi
treatment
rsv
diseas
combin
antivir
therapi
passiv
administ
immunoglobulin
investig
anim
model
children
therapi
ivig
contain
high
level
rsvspecif
antibodi
alon
seem
effect
placebocontrol
trial
children
immunocompromis
small
open
trial
mdacc
combin
therapi
aerosol
ribavirin
hday
high
rsvtiter
ivig
gkg
everi
day
associ
favor
respons
adult
hsct
recipi
patient
undergo
induct
chemotherapi
leukemia
rsv
lower
respiratori
tract
diseas
therapi
initi
prior
respiratori
failur
dana
farber
cancer
institut
combin
therapi
aerosol
ribavirin
hday
rsvivig
gkg
one
dose
similarli
associ
favor
respons
hsct
recipi
clinic
sever
rsv
pneumonia
occur
earli
follow
transplant
subsequ
year
mdacc
util
combin
regimen
similar
respons
although
standard
ivig
frequent
larg
dose
mgkg
qod
substitut
hightit
ivig
therapeut
option
treatment
rsv
includ
use
oral
ribavirin
studi
hsct
recipi
found
safe
less
expens
intraven
aerosol
ribavirin
recommend
option
addit
intraven
inhal
ribavirin
european
confer
infect
leukemia
option
includ
iv
ribavirin
investig
drug
icn
topic
immunoglobulin
administ
aerosol
intraven
ribavirin
rel
eas
administr
iv
ribavirin
attract
high
rate
mortal
signific
case
hemolyt
anemia
make
option
current
problemat
although
european
experi
combin
aerosolizedintraven
ribavirin
favor
intraven
ribavirin
rel
simpl
administ
high
rate
mortal
signific
case
hemolyt
anemia
make
approach
controversi
monotherapi
iv
ribavirin
may
toxic
patient
previous
report
patient
hemorrhag
fever
decis
initi
therapi
aerosol
ribavirin
without
immunotherapi
rsvuri
must
take
consider
mani
factor
includ
patient
risk
develop
seriou
lower
respiratori
tract
diseas
specif
degre
anticip
lymphopenia
potenti
exposur
health
care
worker
medic
psycholog
physic
discomfort
patient
aerosol
therapi
advers
effect
aerosol
ribavirin
bronchospasm
high
cost
drug
well
intens
respiratori
therapi
need
safe
administ
aerosol
ribavirin
need
hospit
frequent
prolong
ribavirin
dose
regimen
patient
alreadi
undergon
condit
therapi
stem
cell
infus
yet
engraft
initi
antivir
therapi
uri
stage
may
benefici
earli
studi
conduct
small
uncontrol
one
studi
conduct
fhcrc
treat
hsct
recipi
upper
tract
rsv
diseas
low
dose
aerosol
ribavirin
administ
high
concentr
mgml
h
day
total
gday
unfortun
patient
develop
pneumonia
seven
die
anoth
studi
evalu
combin
therapi
aerosol
ribavirin
mgkg
ivig
everi
day
patient
two
develop
pneumonia
die
preemptiv
strategi
similar
use
prevent
cmv
diseas
cmv
pneumonia
use
transplant
center
patient
highest
risk
rsv
diseas
progress
preengraft
patient
rsv
detect
first
week
follow
transplant
option
preemptiv
therapi
includ
immunotherapi
ivig
rsvspecif
monoclon
antibodi
although
littl
data
efficaci
immunotherapi
avail
antivir
therapi
hmpv
current
avail
routin
util
ribavirin
activ
vitro
vivo
hmpv
although
control
studi
evid
larg
retrospect
review
treatment
hmpv
pneumonia
human
drug
yet
demonstr
clinic
effect
human
intraven
oral
inhal
ribavirin
alon
combin
ivig
report
potenti
success
therapeut
option
retrospect
analysi
compar
outcom
immunocompromis
patient
hmpv
pneumonia
treat
ribavirin
ivig
ten
untreat
patient
ribavirin
treatment
associ
hypoxemia
similar
mortal
possibl
relat
late
initi
therapi
seattl
studi
describ
hmpv
lower
respiratori
tract
diseas
immunocompromis
children
includ
nine
undergo
hsct
eight
sot
recipi
demonstr
hsct
recipi
evid
sever
diseas
five
eight
hsct
recipi
sot
recipi
lower
tract
diseas
treat
aerosol
ribavirin
three
diagnos
hmpv
pretranspl
posttranspl
period
receiv
ribavirin
ivig
two
addit
children
receiv
aerosol
ribavirin
ribavirin
gener
administ
dose
g
given
three
time
daili
day
two
three
patient
diagnos
hmpv
pretranspl
receiv
ribavirin
ivig
die
aggress
infect
control
strategi
effect
reduc
nosocomi
acquisit
rsv
transplant
recipi
infect
control
strategi
play
crucial
role
prevent
respiratori
viral
infect
effect
strategi
base
understand
potenti
serious
infect
transplant
recipi
knowledg
virus
circul
commun
ongo
surveil
highrisk
patient
continu
educ
patient
famili
member
visitor
staff
regard
potenti
serious
infect
must
repeatedli
emphas
frequent
routin
clinic
screen
highrisk
patient
acut
upper
andor
lower
respiratori
tract
ill
flulik
ill
must
conduct
sampl
respiratori
secret
symptomat
highrisk
patient
routin
perform
pretranspl
posttranspl
health
careacquir
infect
view
sentinel
event
warrant
investig
reaffirm
modif
prevent
strategi
infect
control
strategi
design
prevent
spread
multipl
mode
transmiss
multipl
respiratori
virus
may
circul
commun
concurr
spread
differ
mean
infect
control
measur
may
need
intensifi
commun
hospit
outbreak
intens
durat
infect
control
measur
tailor
risk
seriou
diseas
differ
subset
transplant
recipi
work
real
world
guidelin
prevent
opportunist
infect
among
hsct
recipi
issu
center
diseas
control
prevent
cdc
infecti
diseas
societi
america
european
american
societi
blood
marrow
transplant
guidelin
clearli
present
evidencebas
recommend
rate
strength
recommend
qualiti
support
evid
similar
guidelin
previous
issu
prevent
opportunist
infect
human
immunodefici
viru
prevent
strategi
hsct
recipi
household
contact
close
contact
health
care
worker
clearli
outlin
document
prevent
nosocomi
acquisit
respiratori
viral
infect
hsct
recipi
demonstr
one
prospect
studi
compar
rate
infect
patient
care
protect
environ
patient
care
transplant
unit
infect
control
measur
strongli
encourag
rigidli
enforc
effect
infect
control
intervent
also
demonstr
dramat
declin
frequenc
nosocomi
crv
infect
among
hsct
recipi
care
transplant
unit
implement
aggress
multifacet
infect
control
strategi
although
intens
multifacet
approach
effect
modifi
version
strategi
also
effect
instanc
seattl
cancer
care
allianc
scca
adult
inpati
transplant
unit
use
similar
strategi
except
health
care
worker
visitor
wear
mask
enter
patient
room
howev
worker
intens
screen
sign
symptom
respiratori
ill
prior
enter
unit
restrict
enter
unit
symptomat
similarli
hsct
recipi
respiratori
symptom
transfer
unit
care
transplant
unit
use
modifi
droplet
precaut
person
enter
room
wear
glove
gown
mask
door
room
kept
close
may
feasibl
intens
protect
patient
durat
increas
suscept
respiratori
viral
diseas
protect
strategi
costli
cumbersom
pose
unpleas
restrict
freedom
qualiti
life
patient
famili
problem
compound
grow
trend
discharg
patient
earli
hospit
perform
outpati
hsct
posttranspl
care
transplant
recipi
resid
commun
follow
frequent
outpati
set
anoth
group
infect
control
practic
must
becom
prioriti
prevent
exposur
respiratori
virus
particularli
challeng
among
highrisk
transplant
recipi
live
commun
respiratori
infect
preval
contagi
exampl
protect
measur
outpati
includ
wash
hand
frequent
thoroughli
avoid
close
contact
individu
suffer
respiratori
ill
encourag
close
contact
vigor
practic
respiratori
hygien
mani
case
individu
live
children
effort
may
nearli
imposs
consider
remov
day
care
exposur
young
children
decreas
exposur
transplant
recipi
children
includ
sibl
discuss
famili
rigor
durat
prophylact
measur
need
individu
base
immunolog
statu
patient
risk
seriou
diseas
need
patient
qualityoflif
issu
passiv
immun
immunoglobulin
immunoglobulin
product
human
monoclon
antibodi
activ
studi
pediatr
infant
popul
palivizumab
human
monoclon
antibodi
direct
rsv
f
protein
licens
prevent
rsv
diseas
prematur
infant
infant
congenit
heart
diseas
administ
monthli
inject
month
rsv
season
cost
therapi
led
new
guidelin
use
pediatr
popul
similar
intervent
util
attempt
decreas
morbid
seriou
rsv
diseas
hsct
recipi
direct
proof
effect
yet
demonstr
exampl
passiv
immunoprophylaxi
immunocompromis
patient
evalu
open
trial
conduct
use
hightit
human
rsvig
adult
studi
signific
antibodi
titer
increas
respiratori
virus
extrem
variabl
although
subset
patient
lowest
titer
appear
receiv
greatest
increas
viralspecif
antibodi
cost
potenti
therapi
remain
quit
high
monoclon
rsv
antibodi
palivizumab
synagi
studi
open
label
studi
adult
hsct
recipi
immunoprophylaxi
monoclon
rsv
antibodi
would
prohibit
expens
older
children
adult
may
potenti
protect
rsv
infect
base
pediatr
studi
new
antibodi
product
includ
longlast
monoclon
antibodi
enhanc
activ
rsv
develop
avail
less
expens
price
could
potenti
provid
protect
rsv
patient
pretranspl
immedi
posttranspl
phase
newer
monoclon
antibodi
potenti
neutral
rsv
hmpv
also
describ
offer
hope
newer
prevent
modal
may
protect
virus
screen
transplantrecipi
respiratori
virus
prior
transplant
routin
recommend
base
current
us
intern
transplant
guidelin
howev
assess
viral
shed
infect
symptomat
transplant
candid
prior
transplant
recommend
delay
transplant
base
detect
rsv
hmpv
may
warrant
depend
evalu
risk
benefit
continu
transplant
consequ
postpon
transplant
consid
includ
progress
underli
malign
logist
issu
regard
donor
avail
access
servic
patient
earli
studi
rsv
diagnos
prior
hsct
demonstr
delay
transplant
reduc
risk
pneumonia
follow
transplant
recent
larg
prospect
studi
conduct
patient
hutch
demonstr
nearli
subject
respiratori
virus
detect
pretranspl
overal
patient
viru
detect
prior
transplant
fewer
day
aliv
lower
surviv
day
ahr
ci
compar
patient
virus
hsct
recipi
respiratori
symptom
viru
detect
prior
transplant
mainli
adult
increas
overal
mortal
seen
compar
patient
without
respiratori
virus
detect
higher
rate
pretranspl
infect
sequela
infect
seen
pediatr
patient
detect
respiratori
virus
asymptomat
patient
associ
increas
mortal
data
strengthen
current
guidelin
recommend
patient
respiratori
symptom
prior
transplant
test
respiratori
virus
transplant
delay
feasibl
howev
studi
perform
chiefli
adult
higher
rate
respiratori
virus
document
children
pretranspl
make
routin
screen
pediatr
patient
worthi
investig
experiment
approach
therapi
rsv
antivir
therapi
includ
novel
fusion
inhibitor
nucleosid
agent
small
rna
inhibitori
molecul
hightit
monoclon
antibodi
prepar
two
promis
rsv
antivir
shown
efficaci
challeng
studi
healthi
adult
includ
alio
compound
alio
biopharma
south
san
francisco
ca
oral
antirsv
nucleosid
design
inhibit
rsv
replic
act
viral
polymeras
gilead
scienc
compound
gilead
scienc
foster
citi
ca
oral
bioavail
rsv
fusion
inhibitor
clinic
trial
agent
healthi
young
children
rsv
propos
intern
multicent
placebocontrol
clinic
trial
initi
juli
remain
ongo
adult
hsct
recipi
document
rsv
infect
clinicaltrialsgov
identifi
antivir
agent
develop
rsv
hmpv
vaccin
current
avail
gener
activ
immun
transplant
recipi
unlik
prevent
sever
diseas
seen
first
sever
month
posttranspl
howev
prevent
rsv
infect
famili
staff
nosocomi
spread
viru
use
vaccin
hold
true
promis
benefit
transplant
recipi
promis
advanc
new
vaccin
direct
rsv
hmpv
report
past
decad
progress
evid
rsv
fusionprotein
base
vaccin
live
attenu
vaccin
advanc
understand
pre
postfus
natur
rsv
f
protein
led
increas
work
develop
proteinbas
vaccin
appropri
older
children
adult
pregnant
women
advanc
technolog
better
molecular
understand
rsv
hmpv
result
new
potenti
rsv
candid
vaccin
least
rsv
vaccin
clinic
studi
phase
clinic
studi
one
rsv
f
vaccin
studi
pregnant
women
exampl
live
rsv
vaccin
candid
studi
includ
liveattenu
vaccin
reli
genet
manipul
rsv
genom
vector
viru
vaccin
util
chimpanze
adenoviru
vaccinia
viru
ankara
chimer
virus
contain
backbon
attenu
parainfluenza
f
gene
rsv
ad
chimer
hmpv
vaccin
contain
backbon
avian
hmpv
f
gene
hmpv
although
live
viral
vaccin
unlik
given
transplant
recipi
pretranspl
earli
posttranspl
offer
hope
potenti
control
rsv
hmpv
diseas
famili
member
health
care
worker
futur
